Breast Cancer Incidence Research Articles

A Pilot Study to Show Longitudinal Trends in Health-Related Quality of Life (HRQOL) in a Cohort of Breast Cancer Patients Under Treatment at a Tertiary Healthcare Facility in Bhubaneswar, India.

Breast cancer incidence has overtaken that of cervical cancer among women in India according to the Globacon 2020 reports. Cancer management is also being streamlined at the Center and district levels, such that comprehensive integrated management is offered to cases to optimize the best results. In breast cancer, there are two modes of surgery namely Breast Conservation Surgery(BCS) and Modified Radical Mastectomy (MRM) now over 2 decades, with recommended Chemo radiation depending on the extent of the disease. HRQOL (Health-related Quality of Life) studies have been done in these groups of patients, due to their added relevance in terms of the loss of a vital organ like the breast. EORTC 30 and BR23 are standardized and detailed tools that have been seen to estimate QOL, keeping in mind a whole array of domains that are affected by the disease. To evaluate the "Body Image" and "Quality of life" (QOL) in operated breast cancer patients using BR -23 and EORTC - QLQ- questionnaire at 1month (after surgery) and then 3 to 4 months after surgery. This article attempts to draw a comparison among of EORTC30 and BR 23 scores calculated for 46 breast cancer patients operated during the pandemic time in one center and consenting to repeat the measures at pre-decided three time periods during the course of management. No significant differences are noted in the mean scores for EORTC 30 and BR23 for the two types of surgeries. Visit 1 scores for both modes of surgery are over 75 and by Visit 3 become less than 55 for EORTC. BR 23 (which measures the symptoms core to Breast cancer) at all 3 visits are between 45 to 55. Friedman's test shows that the scores are not significant for age groups, the number of living children, or lifestyle factors like alcohol or tobacco chewing, though quadratic graphs depict the distinct variations in the scores at the 3 times reinforcing the need for follow-up of mental health in these subjects at intervals. The study largely brings out a strong need for repeated follow-up and counseling at regular and short intervals, post-surgery in breast cancer patients. EORTC 30 and BR 23 tools are excellent to use to essay information on the mental health of patients with breast cancer.

Эпидемиологическая характеристика рака молочной железы в Республике Северная Осетия-Алания в 2017-2021 гг. и в период коронавирусной инфекции COVID-19.

The purpose of the study: to identify the features of the incidence and main diagnostic indicators of breast cancer in the Republic of North Ossetia-Alania and assess their change during the spread of coronavirus infection COVID‑19. Materials and methods. The data of the annual reports of the Republican Oncological Dispensary of the Republic of North Ossetia-Alania and the data of the state medical statistics (form No. 7 «Information on malignant neoplasms») for 2012–2021 were studied. The most important diagnostic indicators for breast cancer have been analyzed. A comparative assessment of the indicators in the republic, the Russian Federation and the North Caucasus Federal District is given. Results. The urgency of the problem of oncological morbidity in the Republic of North Ossetia-Alania is due to the increasing prevalence of malignant neoplasms, according to which it occupies the first place in the North Caucasus Federal District. The leading oncological pathology in the female population is breast cancer 26,6% (RF – 21,7%). The epidemiological situation associated with the spread of COVID‑19 coronavirus infection has had a significant impact on cancer incidence in recent years. The rate of newly diagnosed breast cancer incidence in 2021 (44,0 per 100,000 population) was lower than in 2019. The characteristic trends of deterioration of the main diagnostic indicators are revealed. Similar to the indicator for the Russian Federation (25,6%), the rate of active detection of breast cancer decreased (42,6%). Despite the positive dynamics of the detection of the tumor process at stage I, early detection of breast cancer suffers due to a decrease in the detection rate at stage II to 50,2%. A stable growth trend over a five-year period, more than 2 times, of the indicator of the neglect of the tumor process (stage IV), amounting to 16,3% by 2022, was revealed. The detection rate at stages III and IV by 2022 was 32,9% in North Ossetia, 34,5% in the North Caucasus Federal District, and 27.1% in the Russian Federation. In 2021, the mortality rate from breast cancer in the first year after diagnosis in North Ossetia (3,6%) is lower than in the Russian Federation (4,8%) and the North Caucasus Federal District (5,2%). There is a maximum decrease in the five-year survival rate in 2020 to 54,2%, correlating with similar trends in the Russian Federation (56,6%). The morphological verification index, indicating the quality of specialized oncological care, is consistently higher than the national average (99,7%). Conclusion. The improvement of oncological situation in the republic will be facilitated by the implementation of priority areas of the regional program for the fight against oncological diseases, the main task of which is the active detection of malignant neoplasms at early stages and their effective treatment. In order to eliminate the current situation, it is necessary to concentrate efforts to improve the effectiveness of providing oncological care to the population, primarily at the level of outpatient polyclinic health care, and increase the oncological alertness of medical workers. The indicators of the oncological service of the republic related to postcovid complications in oncolo need additional analysis. The indicators of the oncological service of the republic related to postcovoid complications in oncological patients need additional analysis.

The influence of breast screening on breast cancer incidence in England: observational study based on cancer registries and bulletins of the NHS Breast Screening Programme.

To assess the amount of breast cancer overdiagnosis associated with the National Health Service Breast Screening Programme (NHSBSP) that started in 1988 in England. First, numbers of breast cancers in women eligible for breast screening not attending screening were estimated for the period 1995-2019, which were extrapolated to all women. A second method was based on ratios of incidence rates of breast cancers in women aged 50-69 to women aged 70 years or more in 1971-1985. The ratio was used for estimating expected numbers of cancers in 1988-2019, and 1995-2019. From 1995 to 2019, 506,607 non-invasive and invasive breast cancers were diagnosed among women aged 50-64 years (1995-2001) and 50-70 years (2002-2019). A first method estimated that 95,297 cancers were in excess to the number of cancers that would be expected had the NHSBSP not existed. 42,567 screen-detected non-invasive and micro-invasive cancers represented 45.8% of the total excess cancer. 18.8% of all cancers diagnosed among women invited to screening, 25.1% of cancers found in women attending screening, and 35.1% of cancers detected by screening would represent overdiagnosis. A second method estimated that, 18.0% of all cancers diagnosed in 1988-2019, and 18.2% of all cancers diagnosed in 1995-2019 among women invited to screening would represent overdiagnosis. The two independent methods obtained similar estimates of overdiagnosis. The NHS Breast Screening Programme in England is associated with substantial amount of overdiagnosis.

Research Progress of Ultrasound Radiomics in The Diagnosis and Treatment of Breast Cancer

With the advancement of medical research in recent years and the frequent occurrence of different types of cancer, breast cancer has gradually attracted the public’s attention. The incidence of breast cancer is rising, mainly affecting women with a high mortality rate. According to the clinical treatment effect, early diagnosis and early treatment can effectively control the mortality of breast cancer and improve patient’s quality of life. Ultrasound radiomics is an emerging field that can extract quantitative high-dimensional data from ultrasound images. Recently, ultrasound radiomics has been widely used in the clinical treatment of breast cancer. This paper analyzed the research progress of ultrasound radiomics in the diagnosis and treatment of breast cancer.

The incidence of breast cancer in Egyptian females in correlation to different mammographic ACR densities.

The density of breast tissue, radiologically referred to as fibroglandular mammary tissue, was found to be a predisposing factor for breast cancer (BC). However, the stated degree of elevated BC risk varies widely in the literature.

Challenges and Opportunities in Breast Cancer Care in Low-Resourced Countries, Jordan as An Example.

Jordan is a relatively small country with a rapidly growing population and a challenged economy. Breast cancer is the most diagnosed cancer among women worldwide and also in Jordan. Though the age-standardized rate (ASR) of breast cancer incidence is still lower than that in Western societies, the number of newly diagnosed cases continues to increase, involving younger women, and new cases are usually detected at more advanced stages. Improvements in breast cancer care across the health care continuum, including early detection, prevention, treatment, and survivorship and palliative care, have become very visible, but may not match the magnitude of the problem. More organized, goal-oriented work is urgently needed to downstage the disease and improve awareness of, access to, and participation in early detection programs. The cost of recently introduced anti-cancer therapies poses a great challenge, but the impact of these therapies on treatment outcomes, including overall survival, is becoming very noticeable. Though the concept of a multidisciplinary approach to breast cancer treatment is often used at most health care facilities, its implementation in real practice varies significantly. The availability of breast reconstruction procedures, survivorship programs, germline genetic testing, counselling, and palliative care is improving, but these are not widely practiced. In this manuscript, we review the status of breast cancer in Jordan and highlight some of the existing challenges and opportunities.

Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutations

Triple-negative breast cancer (TNBC) patients are more likely to have BRCA1/2 mutations, with a prevalence rate of about 10–20%. Although several studies have analyzed the oncologic outcomes between BRCA1/2 carriers and non-carriers, the impact on breast cancer patients is still unclear. A retrospective review was performed to determine the long-term outcomes of TNBC patients, focusing on the impact of BRCA1/2 mutations. A total of 953 TNBC patients who underwent primary breast cancer surgery from June 2008 to January 2016 were included. We examined long-term outcomes, including contralateral breast cancer (CBC) incidence, recurrence patterns, and survival rates over a median follow-up of 80.9 months (range 3–152 months). 122 patients (12.8%) had BRCA1/2 mutations. BRCA1/2 mutation carriers were significantly younger at diagnosis and more likely to have a family history of breast/ovarian cancer. CBC incidence at 60, 120, and 150 months was significantly higher in BRCA1/2 mutation carriers compared to non-carriers (P = 0.0250, 0.0063, and 0.0184, respectively). However, there were no significant differences in disease-free survival, overall survival, breast cancer-specific survival, or distant-metastasis-free survival between the two groups. BRCA1/2 mutation status was a significant risk factor for CBC (HR = 6.242, P < 0.0001). Interestingly, among 29 patients with CBC recurrence, 24 patients (82.8%) had recurring TNBC subtype and among the CBC recurrence patients, 19 patients (65.5%) resumed chemotherapy. In the TNBC subtype, appropriate genetic testing and counseling are pivotal for surgical decisions like risk-reducing mastectomy (RRM). Furthermore, long-term surveillance is warranted, especially in BRCA1/2 carriers who did not receive RRM.

Model for assessing the influence of quality of life indicators on the breast cancer incidence

Introduction. Malignant neoplasms of the breast are the leading oncological pathology among the female population of the Primorsky region. Identification of the relationship between the incidence rate and quality of life indicators, along with modern diagnostic methods, makes it possible to improve preventive measures to reduce the prevalence in the population at the regional level. Purpose. Development of a regression model that describes the impact of socio-economic indicators of quality of life on the incidence of breast cancer in the population of the Primorsky region. Materials and methods. The initial data sample consisted of seventeen indicators of the quality of life in the population of Primorsky region for the period from 1994 to 2020. To reduce the dimensionality of the data, the principal component method was used, and regression analysis was used to build the model. The quality of the constructed model was checked on the base of the calculation of the coefficient of determination, the standard error, and the approximation error. Results. There were identified 15 indicators of the quality of life in the population that significantly affect the pathology of breast cancer in the Primorsky region. Principal component analysis has made it possible to group the quality of life indicators into three major compartments. The first component explains 80.8% of the variance, the second — 10%, the third — 4%. The first compartment included indicators characterizing the socio-economic aspects of the life of the population, the second — medical and social, and the third — statistical indicators of inequality in monetary incomes of the population, characterizing the social differentiation of society. A regression model has been developed on the principal compartments. Research limitations. The research materials are limited to the results of statistical analysis of 17 indicators of the quality of life of the population of the Primorsky region for the period from 1994 to 2020 and the application of the developed regression model at the regional level. Conclusion. The results of this study made it possible to identify the relationship between the incidence of breast cancer and risk factors and develop a predictive model, which can be useful in planning preventive measures to improve the quality of life and reduce the incidence at the regional level.

Improving Breast Cancer Outcomes for Indigenous Women in Australia.

In Australia, the incidence rate of breast cancer is lower in Indigenous* women than non-Indigenous women; however, the mortality rate is higher, with Indigenous women 1.2 times more likely to die from the disease. This paper provides practical and achievable solutions to improve health outcomes for Indigenous women with breast cancer in Australia. This research employed the Context-Mechanism-Outcome (CMO) framework to reveal potential mechanisms and contextual factors that influence breast cancer outcomes for Indigenous women, stratified into multiple levels, namely, micro (interpersonal), meso (systemic) and macro (policy) levels. The CMO framework allowed us to interpret evidence regarding Indigenous women and breast cancer and provides nine practical ways to improve health outcomes and survival rates.

Factors influencing breast cancer screening practices among women worldwide: a systematic review of observational and qualitative studies

BackgroundThe variation in breast cancer incidence rates across different regions may reflect disparities in breast cancer screening (BCS) practices. Understanding the factors associated with these screening behaviors is crucial for identifying modifiable elements amenable to intervention. This systematic review aims to identify common factors influencing BCS behaviors among women globally.MethodsRelevant papers were sourced from PubMed, Scopus, Embase, and Google Scholar. The included studies were published in English in peer-reviewed journals from January 2000 to March 2023 and investigated factors associated with BCS behaviors.ResultsFrom an initial pool of 625 articles, 34 studies (comprising 29 observational and 5 qualitative studies) with 36,043 participants were included. Factors influencing BCS behaviors were categorized into nine groups: socio-demographic factors, health status history, knowledge, perceptions, cultural factors, cues to action, motivation, self-efficacy, and social support. The quality appraisal scores of the studies ranged from average to high.ConclusionsThis systematic review highlights factors pivotal for policy-making at various levels of breast cancer prevention and assists health promotion professionals in designing more effective interventions to enhance BCS practices among women.

Socioeconomic Deprivation and Invasive Breast Cancer Incidence by Stage at Diagnosis: A Possible Explanation to the Breast Cancer Social Paradox.

In this study, we assessed the influence of area-based socioeconomic deprivation on the incidence of invasive breast cancer (BC) in France, according to stage at diagnosis. All women from six mainland French departments, aged 15+ years, and diagnosed with a primary invasive breast carcinoma between 2008 and 2015 were included (n = 33,298). Area-based socioeconomic deprivation was determined using the French version of the European Deprivation Index. Age-standardized incidence rates (ASIR) by socioeconomic deprivation and stage at diagnosis were compared estimating incidence rate ratios (IRRs) adjusted for age at diagnosis and rurality of residence. Compared to the most affluent areas, significantly lower IRRs were found in the most deprived areas for all-stages (0.85, 95% CI 0.81-0.89), stage I (0.77, 95% CI 0.72-0.82), and stage II (0.84, 95% CI 0.78-0.90). On the contrary, for stages III-IV, significantly higher IRRs (1.18, 95% CI 1.08-1.29) were found in the most deprived areas. These findings provide a possible explanation to similar or higher mortality rates, despite overall lower incidence rates, observed in women living in more deprived areas when compared to their affluent counterparts. Socioeconomic inequalities in access to healthcare services, including screening, could be plausible explanations for this phenomenon, underlying the need for further research.

Oridonin promotes RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress signaling pathway JNK/Nrf2/HO-1

The incidence and mortality of breast cancer, the most common malignant tumor among women in the world, are increasing year by year, which greatly threatens women's health. Ferroptosis is an iron and lipid reactive oxygen species (ROS)-dependent process, a novel form of cell death that is distinct from apoptosis and is closely related to the progression of breast cancer. Inducing the occurrence of ferroptosis in tumor cells can effectively block its malignant progress in vivo. Oridonin (ORI), the primary active ingredient extracted from the Chinese herbal medicine Rabdosia rubescens, has been shown to cause glutathione depletion and directly inhibit glutathione peroxidase 4 induced cell death by ferroptosis, but its mechanism of action in breast cancer remains inadequately elucidated. Therefore, we further investigated whether ORI could promote RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress pathway JNK/Nrf2/HO-1. In our study, we assessed cell survival of RSL3 and ORI treatment by MTT assay, and found that co-treatment with RSL3 and ORI inhibited cell proliferation, as evidenced by the cloning assay. To investigate the ability of ORI to promote RSL3-induced ferroptosis in breast cancer cells, we measured levels of ROS, malondialdehyde, glutathione, superoxide dismutase, and Fe2+ content. Lipid peroxidation, ROS, and mitochondrial membrane potential levels induced by co-treatment of ORI with RSL3 were reversed by ferrostatin-1, further confirming that the cell death induced by RSL3 and ORI was ferroptosis rather than other programmed cell death modes. Moreover, RSL3 and ORI co-treatment regulated the JNK/Nrf2/HO-1 axis, as demonstrated by western blotting and target activator validation. Our results showed that ORI could enhance the inhibitory effect of RSL3 on breast cancer cells viability via the induction of ferroptosis. Mechanistically, it potentiated RSL3-induced ferroptosis in breast cancer cells by activating the JNK/Nrf2/HO-1 axis. This study provides a theoretical basis for the application of ORI based on the mechanism of ferroptosis, and provides potential natural drug candidates for cancer prevention and treatment.

Incidence of Breast Cancer in Younger Women: A Canadian Trend Analysis.

Purpose: Breast cancer (BC) incidence is increasing globally. Age-specific BC incidence trend analyses are lacking for women under age 50 in Canada. In this study, we evaluate the incidence trends in breast cancer in women under age 50 in Canada and compare them with corresponding trends among women 50 to 54. Methods: BC case counts were obtained from the National Cancer Incidence Reporting System (1984-1991) and the Canadian Cancer Registry (1992-2019) both housed at Statistics Canada. Population data were also obtained from Statistics Canada. Annual female BC age-specific incidence rates from 1984 to 2019 were derived for the following age groups: 20 to 29, 30 to 39, 40 to 49, 40 to 44, 45 to 49, and 50 to 54. Changes in trends in age-specific BC incidence rates, if any, and annual percent changes (APCs) for each identified trend, were determined using JoinPoint. Results: Statistically significant increasing trends in BC incidence rates were noted for almost all age groups: since 2001 for 20 to 29 (APC = 3.06%, P < .001); since 2009 for 30 to 39 (APC = 1.25%, P = .007); since 1984 for both 40 to 49 (APC = 0.26%, P < .001) and 40 to 44 (APC = 0.19%, P = .011), increased since 2015 for 40 to 49 (APC = 0.77%, P = .047); and since 2005 for 50 to 54 (APC = 0.38%, P = .022). Among women 45 to 49 there was a non-significant increase since 2005 (APC = 0.24, P = .058). Statistically significant average annualized increases in BC incidence rates were observed for each age group studied. Conclusions: Examining age-specific incidence rates formed a more complete picture of BC time trends with significant increasing trends in the incidence of BC among women in their 20s, 30s, 40s, and early 50s. A greater awareness regarding the increasing number of cases of BC in women younger than 50 is critical to allow for earlier diagnosis with its resultant reduced mortality and morbidity.

Unlocking the Potential Thorough Analysis of Machine Learning for Breast Cancer Diagnosis

To forecast breast cancer with the goal of giving a thorough rundown of current developments in the area. Given that breast cancer is among the world's leading causes of mortality for women; improving patient outcomes requires early detection. This study looks into the ability to predict outcomes using a variety of machine learning (ML) models, including random forests, logistic regression, support vector machines, decision trees, k- nearest neighbours, and deep learning neural networks, in predicting the incidence of breast cancer from patient data, including genetic markers, imaging results, and demographics. Aims to provide a comprehensive analysis of presetn advancements, obstacles, and prospects in the field of CNN-based techniques for breast cancer identification. The review begins by outlining the urgent need for reliable and accurate diagnostic methods for breast cancer, highlighting the critical role that early identification plays in enhancing patient outcomes. Which delves into the intricate architecture of CNNs, revealing its unique applicability to mammography image analysis as well as their innate advantages in image classification tasks. Important topics of discussion include the various CNN architectures used for two- and three- dimensional (2D) imaging methods used in breast cancer diagnosis.

Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis.

In the Women's Health initiative (WHI) randomized clinical trial, conjugated equine estrogen (CEE)-alone significantly reduced breast cancer incidence (P = 0.005). As cohort studies had opposite findings, other randomized clinical trials were identified to conduct a meta-analysis of estrogen-alone influence on breast cancer incidence. We conducted literature searches on randomized trials and: estrogen, hormone therapy, and breast cancer, and searches from a prior meta-analysis and reviews. In the meta-analysis, for trials with published relative risks (RR) and 95% confidence intervals (CI), each log-RR was multiplied by weight = 1/V, where V = variance of the log-RR, and V was derived from the corresponding 95% CI. For smaller trials with only breast cancer numbers, the corresponding log-RR = (O - E)/weight, where O is the observed case number in the oestrogen-alone group and E the corresponding expected case number, E = nP. Findings from 10 randomized trials included 14,282 participants and 591 incident breast cancers. In 9 smaller trials, with 1.2% (24 of 2029) vs 2.2% (33 of 1514) randomized to estrogen-alone vs placebo (open label, one trial) (RR 0.65 95% CI 0.38-1.11, P = 0.12). For 5 trials evaluating estradiol formulations, RR = 0.63 95% CI 0.34-1.16, P = 0.15. Combining the 10 trials, 3.6% (262 of 7339) vs 4.7% (329 of 6943) randomized to estrogen-alone vs placebo (overall RR 0.77 95% CI 0.65-0.91, P = 0.002). The totality of randomized clinical trial evidence supports a conclusion that estrogen-alone use significantly reduces breast cancer incidence.

Hormone replacement therapy and the incidence and prevalence of breast cancer: an integrative review

The objective of this study was to carry out an integrative review an integrative review to analyze the incidence and prevalence of breast cancer after hormone replacement therapy. This integrative review followed several steps, including identifying the topic, structuring the research question using the PICO strategy, defining inclusion criteria, selecting articles, evaluating and analyzing selected studies, interpreting the results and presenting the review. The use of hormone replacement therapy (HRT) is linked to a significantly increased risk of breast cancer, especially with combination therapy. The risk increases with time of use and persists after discontinuation. Although some studies have found a significant risk, estrogen-only therapy carries a lower risk, particularly for long-term use. Hormone replacement therapy, especially the combined formulation of estrogen and progestogen, is associated with a significant increase in the risk of breast cancer, persisting after discontinuation. The estrogen-only formulation has a lower risk. The duration of HRT and body mass index (BMI) also influence the risk.

Ethnic disparities in breast cancer patterns in Brazil: examining findings from population-based registries.

To investigate breast cancer (BC) incidence and mortality rates among specific racial groups in Brazil. BC incidence was evaluated from 2010 to 2015, using Brazilian Population-Based Cancer Registries, incorporating crude ratios and annual average percentage change (AAPC). Clinical and sociodemographic data from 2000 to 2019 were obtained from Hospital-Based Cancer Registries. Mortality data from 2000 to 2020 were sourced from the National Mortality Information System, comparing White women and Black women. Across 13 Brazilian registries, 70,896 new BC cases were reported from 2010 to 2015. The median BC incidence rate was notably higher for White women (101.3 per 100,000) compared to Black women (59.7 per 100,000). In the general population, non-significant decrease in annual BC incidence was observed (AAPC = - 1.2; p = 0.474). Black women were more likely to live in underdeveloped areas, have lower education levels, live without a partner, and have higher alcohol consumption as compared to White women. A higher proportion of Black women received advanced-stage diagnoses (60.1% versus 50.6%, p < 0.001). BC-related mortality analysis showed 271,002 recorded deaths, with significant increase in BC-specific mortality rates in both racial groups. Black women displayed an AAPC of 2.3% (p < 0.001), while White women demonstrated a moderately elevated AAPC of 0.6% (p < 0.001). This study underscores the need for targeted policies to address disparities in access to early detection and proper treatment, particularly for Black women in underprivileged regions, aiming to improve the survival rates of Brazilian women grappling with BC.

Validation of prostate and breast cancer detection artificial intelligence algorithms for accurate histopathological diagnosis and grading: a retrospective study with a Japanese cohort

Prostate and breast cancer incidence rates have been on the rise in Japan, emphasising the need for precise histopathological diagnosis to determine patient prognosis and guide treatment decisions. However, existing diagnostic methods face numerous challenges and are susceptible to inconsistencies between observers. To tackle these issues, artificial intelligence (AI) algorithms have been developed to aid in the diagnosis of prostate and breast cancer. This study focuses on validating the performance of two such algorithms, Galen Prostate and Galen Breast, in a Japanese cohort, with a particular focus on the grading accuracy and the ability to differentiate between invasive and non-invasive tumours. The research entailed a retrospective examination of 100 consecutive prostate and 100 consecutive breast biopsy cases obtained from a Japanese institution. Our findings demonstrated that the AI algorithms showed accurate cancer detection, with AUCs of 0.969 and 0.997 for the Galen Prostate and Galen Breast, respectively. The Galen Prostate was able to detect a higher Gleason score in four adenocarcinoma cases and detect a previously unreported cancer. The two algorithms successfully identified relevant pathological features, such as perineural invasions and lymphovascular invasions. Although further improvements are required to accurately differentiate rare cancer subtypes, these findings highlight the potential of these algorithms to enhance the precision and efficiency of prostate and breast cancer diagnosis in Japan. Furthermore, this validation paves the way for broader adoption of these algorithms as decision support tools within the Asian population.

An Examination and Evaluation of the Rising Incidence of Breast Cancer among Women and Impact on Society

The number of deaths from breast cancer is rising rapidly year by year. The most common kind of cancer named as breast cancer is an overall and the leading cause for women death rate all over India. A cancer patient can go for a long and healthy life by early detection and proper treatment of cancer. In India, where advanced stages of the disease at diagnosis, combined with rising incidence and death rates, make breast cancer the most frequent cancer among women now a days. It is demand of time to spread a better cancer literacy awareness among women of India. Therefore, we did secondary data collection using literature review in order to know patient survival parameters and treatment strategies, with high degree of accuracy in breast cancer detection . Online and offline structured questioners has been used to collect primary data from various participants. This research paper also used a large dataset of breast cancer patients from the UCI Machine Learning Repository. Our paper examined that there is a very low cancer literacy about breast cancer risk factors in India , irrespective of socio-economic and educational background of participant women . There is an urgent need for offline and online awareness programmes to improve cancer literacy in Indian Women .

Investigating the detection of breast cancer with deep transfer learning using ResNet18 and ResNet34

A lot of underdeveloped nations particularly in Africa struggle with cancer-related, deadly diseases. Particularly in women, the incidence of breast cancer is rising daily because of ignorance and delayed diagnosis. Only by correctly identifying and diagnosing cancer in its very early stages of development can be effectively treated. The classification of cancer can be accelerated and automated with the aid of computer-aided diagnosis and medical image analysis techniques. This research provides the use of transfer learning from a Residual Network 18 (ResNet18) and Residual Network 34 (ResNet34) architectures to detect breast cancer. The study examined how breast cancer can be identified in breast mammography pictures using transfer learning from ResNet18 and ResNet34, and developed a demo app for radiologists using the trained models with the best validation accuracy. 1, 200 datasets of breast x-ray mammography images from the National Radiological Society’s (NRS) archives were employed in the study. The dataset was categorised as implant cancer negative, implant cancer positive, cancer negative and cancer positive in order to increase the consistency of x-ray mammography images classification and produce better features. For the multi-class classification of the images, the study gave an average accuracy for binary classification of benign or malignant cancer cases of 86.7% validation accuracy for ResNet34 and 92% validation accuracy for ResNet18. A prototype web application showcasing ResNet18 performance has been created. The acquired results show how transfer learning can improve the accuracy of breast cancer detection, providing invaluable assistance to medical professionals, particularly in an African scenario.